The Expanding Therapeutic Potential of Neuronal KCC2

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Jan 23

PMID 31963584

Citations 27

Authors

Bor Luen Tang

Affiliations

Soon will be listed here.

Abstract

Dysfunctions in GABAergic inhibitory neural transmission occur in neuronal injuries and neurological disorders. The potassium-chloride cotransporter 2 (KCC2, SLC12A5) is a key modulator of inhibitory GABAergic inputs in healthy adult neurons, as its chloride (Cl) extruding activity underlies the hyperpolarizing reversal potential for GABA receptor Cl currents (E). Manipulation of KCC2 levels or activity improve symptoms associated with epilepsy and neuropathy. Recent works have now indicated that pharmacological enhancement of KCC2 function could reactivate dormant relay circuits in an injured mouse's spinal cord, leading to functional recovery and the attenuation of neuronal abnormality and disease phenotype associated with a mouse model of Rett syndrome (RTT). KCC2 interacts with Huntingtin and is downregulated in Huntington's disease (HD), which contributed to GABAergic excitation and memory deficits in the R6/2 mouse HD model. Here, these recent advances are highlighted, which attest to KCC2's growing potential as a therapeutic target for neuropathological conditions resulting from dysfunctional inhibitory input.

Citing Articles

Impaired Molecular Mechanisms Contributing to Chronic Pain in Patients with Hidradenitis Suppurativa: Exploring Potential Biomarkers and Therapeutic Targets.

Radhakrishna U, Kuracha M, Hamzavi I, Saiyed N, Prajapati J, Rawal R Int J Mol Sci. 2025; 26(3).

PMID: 39940809 PMC: 11817842. DOI: 10.3390/ijms26031039.

Uncovering novel KCC2 regulatory motifs through a comprehensive transposon-based mutant library.

Uvarov P, Fudo S, Karakus C, Golubtsov A, Rotondo F, Sukhanova T Front Mol Neurosci. 2025; 17:1505722.

PMID: 39881966 PMC: 11774852. DOI: 10.3389/fnmol.2024.1505722.

Development of KCC2 therapeutics to treat neurological disorders.

Kadam S, Hegarty S Front Mol Neurosci. 2024; 17:1503070.

PMID: 39720463 PMC: 11666659. DOI: 10.3389/fnmol.2024.1503070.

Continuous Use During Disuse: Mechanisms and Effects of Spontaneous Activity of Unloaded Postural Muscle.

Shenkman B, Kalashnikov V, Sharlo K, Turtikova O, Bokov R, Mirzoev T Int J Mol Sci. 2024; 25(22).

PMID: 39596527 PMC: 11594575. DOI: 10.3390/ijms252212462.

Novel voltage-dependent Cl channels in striatal medium spiny neurons are unrelated to ClC-1 or other known Ca-induced Cl channel/transporter types.

Yarotskyy V, Contois L, Hahn Y, Nass S, Knapp P, Hauser K Neurosci Lett. 2024; 844():138032.

PMID: 39491780 PMC: 11727886. DOI: 10.1016/j.neulet.2024.138032.

References

Cardarelli R, Jones K, Pisella L, Wobst H, McWilliams L, Sharpe P . The small molecule CLP257 does not modify activity of the K-Cl co-transporter KCC2 but does potentiate GABA receptor activity. Nat Med. 2017; 23(12):1394-1396. PMC: 7371006. DOI: 10.1038/nm.4442. View

Hou X, Weng Y, Wang T, Ouyang B, Li Y, Song Z . Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain. Neuroscience. 2018; 377:138-149. DOI: 10.1016/j.neuroscience.2018.02.026. View

Kiyoi H, Kawashima N, Ishikawa Y . FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2019; 111(2):312-322. PMC: 7004512. DOI: 10.1111/cas.14274. View

Milne J, Lambert P, Schenk S, Carney D, Smith J, Gagne D . Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007; 450(7170):712-6. PMC: 2753457. DOI: 10.1038/nature06261. View

Llorens-Martin M, Jurado J, Hernandez F, Avila J . GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7:46. PMC: 4033045. DOI: 10.3389/fnmol.2014.00046. View

Carter B, Sullivan B, Landers J, Kadam S . Dose-dependent reversal of KCC2 hypofunction and phenobarbital-resistant neonatal seizures by ANA12. Sci Rep. 2018; 8(1):11987. PMC: 6086916. DOI: 10.1038/s41598-018-30486-7. View

Moore Y, Deeb T, Chadchankar H, Brandon N, Moss S . Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures. Proc Natl Acad Sci U S A. 2018; 115(40):10166-10171. PMC: 6176565. DOI: 10.1073/pnas.1810134115. View

Hubner C, Stein V, Hermans-Borgmeyer I, Meyer T, Ballanyi K, Jentsch T . Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition. Neuron. 2001; 30(2):515-24. DOI: 10.1016/s0896-6273(01)00297-5. View

Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G . TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci. 2006; 26(37):9385-93. PMC: 6674601. DOI: 10.1523/JNEUROSCI.1246-06.2006. View

10.

Saitsu H, Watanabe M, Akita T, Ohba C, Sugai K, Ong W . Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Sci Rep. 2016; 6:30072. PMC: 4951812. DOI: 10.1038/srep30072. View

11.

Chahrour M, Jung S, Shaw C, Zhou X, Wong S, Qin J . MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320(5880):1224-9. PMC: 2443785. DOI: 10.1126/science.1153252. View

12.

Labbadia J, Morimoto R . Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci. 2013; 38(8):378-85. PMC: 3955166. DOI: 10.1016/j.tibs.2013.05.003. View

13.

Rossignol S, Frigon A . Recovery of locomotion after spinal cord injury: some facts and mechanisms. Annu Rev Neurosci. 2011; 34:413-40. DOI: 10.1146/annurev-neuro-061010-113746. View

14.

He Q, Arroyo E, Smukowski S, Xu J, Piochon C, Savas J . Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice. Mol Psychiatry. 2018; 24(11):1732-1747. PMC: 6204122. DOI: 10.1038/s41380-018-0048-y. View

15.

Damier P, Hammond C, Ben-Ari Y . Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. Clin Neuropharmacol. 2016; 39(1):57-9. DOI: 10.1097/WNF.0000000000000114. View

16.

Urbanska M, Kazmierska-Grebowska P, Kowalczyk T, Caban B, Nader K, Pijet B . GSK3β activity alleviates epileptogenesis and limits GluA1 phosphorylation. EBioMedicine. 2018; 39:377-387. PMC: 6355642. DOI: 10.1016/j.ebiom.2018.11.040. View

17.

Naziroglu M . TRPV1 Channel: A Potential Drug Target for Treating Epilepsy. Curr Neuropharmacol. 2015; 13(2):239-47. PMC: 4598436. DOI: 10.2174/1570159x13666150216222543. View

18.

Chen C, Li W, Qu K, Chen C . Piperine exerts anti-seizure effects via the TRPV1 receptor in mice. Eur J Pharmacol. 2013; 714(1-3):288-94. DOI: 10.1016/j.ejphar.2013.07.041. View

19.

Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M . A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012; 2:e202. PMC: 3565189. DOI: 10.1038/tp.2012.124. View

20.

Shih H, Kuan Y, Shyu B . Targeting brain-derived neurotrophic factor in the medial thalamus for the treatment of central poststroke pain in a rodent model. Pain. 2017; 158(7):1302-1313. PMC: 5472007. DOI: 10.1097/j.pain.0000000000000915. View